Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Permanent lenke
https://hdl.handle.net/10037/36712Dato
2024-09-23Type
Journal articleTidsskriftartikkel
Peer reviewed
Forfatter
Solmi, Marco; Miola, Alessandro; Capone, Federico; Pallottino, Simone; Højlund, Mikkel; Firth, Joseph; Siskind, Dan; Holt, Richard IG; Corbeil, Olivier; Cortese, Samuele; Dragioti, Elena; Rietz, Ebba Du; Nielsen, Rene Ernst; Nordentoft, Merete; Fusar-Poli, Paolo; Hartman, Catharina A; Høye, Anne; Koyanagi, Ai; Larsson, Henrik; Lehto, Kelli; Lindgren, Peter; Manchia, Mirko; Skonieczna-Żydecka, Karolina; Stubbs, Brendon; Vancampfort, Davy; Vieta, Eduard; Taipale, Heidi; Correll, Cristoph U.Sammendrag
Areas covered - We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.
Expert opinion - To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications’ and patient’s weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.